To Save Pepaxto, Oncopeptides Throws Shade At IMiD Use In Elderly Myeloma Patients

 
• By Sue Sutter

Seeking to head off US FDA withdrawal of its alkylating agent, sponsor says pomalidomide comparator in OCEAN confirmatory trial rendered overall survival results difficult to interpret because immunomodulatory drugs are detrimental in elderly patients. CDER says IMiD analysis is exploratory and cannot negate adverse overall survival finding with Pepaxto.

Chain link
Oncopeptides says its withdrawal appeal brief for Pepaxto describes the 'missing link' for why elderly myeloma patients have not seen improved survival. • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards